Early Diagnosis and Treatment Strategies for Prostate Cancer

De-Jun Hu ( Deyang People's Hospital,Mianyang,618000,China )

https://doi.org/10.37155/2717-5278-0602-7

Abstract

Prostate cancer, as a common malignant tumor in males, requires preventive measures and early screening to reduce the incidence rate and improve treatment outcomes. For high-risk groups such as men with a family history, specifc racial backgrounds, or advanced age, it is recommended to start prostate cancer screening at the age of 45 or 10 years earlier than the earliest onset age in the family. Screening methods include PSA testing, digital rectal examination (DRE), and more precise imaging tests. For the general population, prostate cancer screening is typically initiated at the age of 50, with a screening frequency of once a year, primarily using PSAtesting and DRE. Additionally, maintaining a healthy lifestyle, such as balanced diet, moderate exercise, and avoiding smoking and alcohol, can also help reduce the risk of prostate cancer. Regular screening and a healthy lifestyle can effectively prevent the occurrence of prostate cancer and enable early treatment of detected lesions, thereby improving patient survival rates and quality of life.

Keywords

Prostate; Cancer; Early Diagnosis; Treatment Strategies

Full Text

PDF

References

[1]Yin Guicao, Tian Haoyu, Tian Feng, et al. Study on Early Diagnosis and Treatment of Prostate Cancer Based on PSA Screening[J]. Journal of Bengbu Medical College, 2023(4): 441-444.
[2]Qiao Junwei, Meilinuer Abudourexiti, Shen Rongfang, et al. Study on the Impact of Al^(18)F-PSMA-BCH Scan on Early Diagnosis and Treatment Decision of Biochemical Recurrence of Prostate Cancer[J]. Chinese Medical Equipment, 2024(2): 79-83.
[3]Niu Xiangnan, Zhang Yanga. Research Progress on Endocrine Therapy for Advanced Prostate Cancer[J]. Modern Oncology Medicine, 2024(5): 973-977.

Copyright © 2024 De-Jun Hu Creative Commons License Publishing time:2024-04-30
This work is licensed under a Creative Commons Attribution 4.0 International License